en.Wedoany.com Reported - India's Sun Pharmaceutical Industries Ltd. announced it will acquire U.S.-based Organon in an all-cash transaction valued at $11.75 billion. Organon, which was spun off from Merck in 2021, focuses on women's health and essential medicines, with a portfolio of over 70 products and operations spanning 140 countries. For the fiscal year ending December 31, 2025, Organon reported revenue of $6.2 billion and adjusted EBITDA of $1.9 billion.

Dilip Shanghvi, Executive Chairman of Sun Pharma, stated: "This transaction presents a significant opportunity for Sun Pharma to advance its vision of 'Connecting People, Touching Lives.'" Kirti Ganorkar, Managing Director of Sun Pharma, noted that the combined entity will strengthen its global presence and become a preferred partner for acquiring and launching new products.

Upon completion of the transaction, Sun Pharma is expected to rank among the top 25 global pharmaceutical companies, with combined revenues reaching $12.4 billion. It will also become a top-three player in women's health and the seventh-largest biosimilar company worldwide. The deal has been approved by the boards of directors of both companies and is expected to close in early 2027, subject to regulatory and shareholder approvals.

On the financial advisory front, J.P. Morgan and Jefferies are serving as advisors to Sun Pharma, with financing provided by Citigroup, JPMorgan Chase Bank, and MUFG Bank. Morgan Stanley and Goldman Sachs are acting as financial advisors to Organon.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com